Image-guided stereotactic body radiation therapy for localized prostate cancer

Tumori

Volumn 97, Issue 1, 2011, Pages 43-48

  Kang, Jin Kyu ^a   Cho, Chul Koo ^a   Choi, Chul Won ^a   Yoo, Seong Yul ^a   Kim, Mi Sook ^a   Yang, Kwang Mo ^a   Yoo, Hyung Jun ^a   Kim, Jin Ho ^a   Seo, Young Seok ^a   Lee, Dong Han ^a   Jo, MoonKi ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

CyberKnife; Localized prostate cancer; Stereotactic body radiation therapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER LOCALIZATION; CAUSE SPECIFIC SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; IMAGE ANALYSIS; KOREA; MALE; PATIENT SAFETY; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RECTUM DISEASE; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; UROGENITAL TRACT DISEASE;

ADENOCARCINOMA; AGED; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOSURGERY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79953860825     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/611.7137     Document Type: Article

References (22)

1. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ: Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer, 2: 37, 2002.
2. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA, 280: 969-974, 1998. (Pubitemid 28445094)
3. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L, Lebesque JV: Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol, 24: 1990-1996, 2006.
4. Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A: A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys, 59: 380-385, 2004. (Pubitemid 38622589)
5. Brenner DJ, Hall EJ: Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys, 43: 1095-1101, 1999. (Pubitemid 29144800)
6. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP: Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys, 52: 6-13, 2002. (Pubitemid 34041562)
7. Brenner DJ: Hypofractionation for prostate cancer radiotherapy- what are the issues? Int J Radiat Oncol Biol Phys, 57: 912-914, 2003.
8. Fowler J, Chappell R, Ritter M: Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys, 50: 1021-1031, 2001.
9. Fowler JF, Ritter MA, Chappell RJ, Brenner DJ: What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys, 56: 1093-1104, 2003.
10. Yeoh EE, Holloway RH, Fraser RJ, Botten RJ, Di Matteo AC, Butters J, Weerasinghe S, Abeysinghe P: Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys, 66: 1072-1083, 2006. (Pubitemid 44633501)
11. Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H, Brundage M, Kwan W: Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol, 23: 6132-6138, 2005.
12. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A: Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys, 68: 1424-1430, 2007. (Pubitemid 47176809)
13. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J: Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys, 67: 1099-1105, 2007.
14. Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G: High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys, 61: 1306-1316, 2005. (Pubitemid 40470411)
15. Yoshioka Y, Nose T, Yoshida K, Oh RJ, Yamada Y, Tanaka E, Yamazaki H, Inoue T, Inoue T: High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys, 56: 213-220, 2003. (Pubitemid 36403694)
16. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA, 280: 969-974, 1998. (Pubitemid 28445094)
17. Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A:What dose of external-beamradiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys, 68: 682-689, 2007.
18. Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, Hunt M, Greenstein S, Amols H: Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys, 71: 330-337, 2008.
19. Tang CI, Loblaw DA, Cheung P, Holden L, Morton G, Basran PS, Tirona R, Cardoso M, Pang G, Gardner S, Cesta A: Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. Clin Oncol (R Coll Radiol), 20: 729-737, 2008.
20. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, Moore AR, Morgan RC, Russell JM, Scrase CD, Stephens RJ, Syndikus I, Parmar MK, RT01 collaborators: Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol, 8: 475-487, 2007.
21. Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A: Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys, 63: 1463-1468, 2005. (Pubitemid 41628043)
22. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr: Stereotactic body radiotherapy for localized prostate cancer: interimresults of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys, 73: 1043-1048, 2009.